硫堇相关的专利数据

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
61	Emulsion that is compatible with reactive sulfide/pyrite ores	EP91305117.3	1991-06-06	EP0460952A3	1992-05-20	Cranney, Don H.; Maxfield, Blake T.
The water-in-oil emulsion explosives of this invention contain a water-immiscible organic fuel as a continuous phase, an emulsified inorganic oxidizer salt solution as a discontinuous phase, an emulsifier, gas bubbles or an air entraining agent for sensitization, and from about 1% to about 30% by weight of the composition urea for stabilization against thermal degradation with reactive sulfide/pyrite ores. The invention also relates to a method of using such explosives.
62	Thiogallate phosphor and white light emitting device employing the same	US12282255	2006-03-10	US07998365B2	2011-08-16	Kyung Nam Kim; Sang Mi Park; Tomizo Matsuoka
The present invention relates to a thiogallate phosphor which is excited by ultraviolet or blue light to emit light with a relatively longer wavelength than that of the ultraviolet or blue light. The phosphor is expressed as a general formula of (A1-x-yEuxMIIIy)(B2-yMIIy)S4, wherein 0.005
63	Fused aromatic-spiropiperidine oxazepinones(and thiones)	US60265	1987-06-10	US4746655A	1988-05-24	Albert D. Cale, Jr.
Novel aromatic-spiropiperidineoxazepinones and thiones exhibiting antihistamine activity are disclosed having the formula: ##STR1## wherein A represents an aromatic ring, selected from benzo when Z is carbon or pyrido[3,2-f] when Z is nitrogen either of which rings may be optionally substituted on carbon;B is selected from oxygen or sulfur;R.sup.1 is selected from the group consisting of loweralkyl, cycloalkyl, cycloalkyl-loweralkyl or phenyl-loweralkyl of which phenyl may be optionally substituted;R is selected from the group consisting of loweralkyl, cycloalkyl or phenyl-loweralkyl of which phenyl may be optionally substituted and the pharmaceutically acceptable salts thereof and novel chemical intermediates in the preparation thereof.
64	Certain substituted-tricyclic quinazolin-thiones used as brochodilators	US32507873	1973-01-19	US3883652A	1975-05-13	HARDTMANN GOETZ E
The compounds are substituted-tricyclic quinazolin-thiones of the class of imidazo(2,1-b)quinazolin-5-thiones and pyrimido(2,1b)quinazolin-6-thiones, e.g., 2,3-dihydro-10-(4''-fluorobenzyl)imidazo (2,1-b)quinazolin-5(10H)-thione, useful as bronchodilator agents.
65	Method of separating thionine and its N-methyl derivatives from each other	US668051	1976-03-18	US4003892A	1977-01-18	Walter Lohr; Norbert Grubhofer; Inge Sohmer; Dietrich Wittekind
Mixtures of cationic thiazine dyes containing two or more members of the group consisting of thionine, azure A, azure B, azure C, and methylene blue may be resolved into pure individual compounds by column chromatography on slica gel using as a solvent system a mixture of water, acetic acid, and formic acid. The several fractions eluted sequentially from the column contain the pure individual dyes in the formate or acetate form. Because high solubility is essential for use of the dyes in staining blood smears, the acetates or formates are converted to the chlorides by adsorption on a solid substrate and contact with NaCl solution, elution with methanol, and recovery of the solid chlorides from the methanol solution.
66	Hydrocarbon desulfurization with a rhenium catalyst on siliceous carrier material	US3598725D	1969-03-20	US3598725A	1971-08-10	HILFMAN LEE
A CATALYST FOR EFFECTING THE DESULFURIZATION OF SULFUROUS, HYDROCARBONACEOUS CHARGES STOCKS. THE CATALYST COMPRISES A COMPOSITE OF A SILICEOUS CARRIER MATERIAL COMBINED WITH RHENIUM SULFIDE. THE RHENIUM SULFIDE IS PRESENT IN AN AMOUNT OF FROM 0.01% TO ABOUT 2.0% BY WEIGHT, CALCULATED AS THE ELEMENTAL METAL, AND IS COMBINED WITH ONE OR MORE SULFIDED METALLIC COMPONENETS FROM GROUPS VI-B AND THE IRON-GROUP. THE USE OF THE RHENIUM COMPONENET IMPARTS ADDITIONAL HYDROGENATION ACTIVITY TO THE CATALYST.
67	Process for the preparation of aromatic-1,4-oxazepinones and thiones	US652017	1984-09-19	US4610819A	1986-09-09	Young S. Lo; Albert D. Cale, Jr.
A process for the preparation of 1,4-oxazepinones and thiones having the formula: ##STR1## wherein A is an aromatic ring selected from benzene, naphthalene, quinoline or pyridine; n is 1 to 3; Z is an amino radical; R is hydrogen, loweralkyl, cycloalkyl or phenylloweralkyl; and R.sup.4 and R.sup.5 are hydrogen and loweralkyl starting from chloroaromatic carboxylates and alkanolamines is disclosed.
68	BIOCIDE COMPOSITION COMPRISING ZINC PYRITHIONE AND A PYRROLE DERIVATIVE	EP07751611.0	2007-02-22	EP1998619B1	2017-05-10	WALDRON, Craig; MARTIN, Robert

69	알파-이소-쿠베베네를 유효성분으로 포함하는 신경 질환의 예방 또는 치료용 조성물	KR1020140056508	2014-05-12	KR101637433B1	2016-07-08	최영환; 박순영; 박근태; 김영훈; 강종구; 김철민
본발명은알파-이소-쿠베베네를유효성분으로포함하는신경질환용조성물에관한것이다. 본발명에따른알파-이소-쿠베베네는단백질의발현및 신경전달의조절을통해서신경세포보호함으로써, 신경질환을개선, 치료또는예방하는효과가뛰어나고, 장기간식품의원료로사용된식물의추출물에서분리된천연물로써안정성이뛰어나, 장기간치료용의약또는건강식품에포함하여도부작용이일어나지않는효과를갖는다.
70	Leuco derivatives of sulfureted gallocyanins and process of making same.	US1185215	1915-03-03	US1188259A	1916-06-20	ENGI GADIENT; GRIESHABER FRITZ

71	BIOCIDE COMPOSITION COMPRISING ZINC PYRITHIONE AND A PYRROLE DERIVATIVE	EP17167037.5	2007-02-22	EP3231283A1	2017-10-18	WALDRON, Craig; MARTIN, Robert
The present invention is directed to a biocidal composition comprising a blend of zinc pyrithione and 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile (traloypryil) wherein said biocidal composition is copper free or low copper content. A coating composition comprising this biocidal composition as well as a method of coating a substrate and a coated wood, plastic, leather vinyl or metal substrate are also disclosed.
72	Chemical intermediates in the preparation of aromatic-1,4-oxazepinones and thiones	US840811	1986-03-18	US4783535A	1988-11-08	Young S. Lo; Albert D. Cale, Jr.
A process for the preparation of 1,4-oxazepinones and thiones having the formula: ##STR1## wherein A is an aromatic ring selected from benzene, naphthalene, quinoline or pyridine; n is 1 to 3; Z is an amino radical; R is hydrogen, loweralkyl, cycloalkyl or phenylloweralkyl; and R.sup.4 and R.sup.5 are hydrogen and loweralkyl starting from chloroaromatic carboxylates and alkanolamines is disclosed. The oxazepinones and oxazepinethiones prepared by the process have utility as antihistaminics with low sedative potential. Novel intermediate compounds are also disclosed.
73	High purity diaminophenothiazinium compounds including methylthioninium chloride (MTC)	US12875465	2010-09-03	US09242946B2	2016-01-26	John Mervyn David Storey; James Peter Sinclair; Colin Marshall; Han Wan Tan; Claude Michel Wischik
This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including Methylhioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt-formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases.
74	Bis-(triethylphosphine)platinum(II) complexes with thiones as anti cancer agents	US15008889	2016-01-28	US09561237B1	2017-02-07	Anvar Husain Abdul Kadir Isab; Muhammad Altaf
Platinum(II) complexes having mixed ligands as anticancer agents. The central platinum atom is coordinated by two phosphine ligands and two heterocyclic thione ligands. Each heterocyclic thione ligand has a five-, six- or seven-membered heterocyclic ring with two nitrogen atoms at positions 1 and 3 of the ring and a thiocarbonyl group at position 2. Pharmaceutical compositions incorporated the platinum(II) complexes, methods of synthesizing the complexes and methods of treating cancers with the complexes or pharmaceutical compositions thereof are also described.
75	High purity diaminophenothiazinium compounds including methylthioninium chloride (MTC)	US15000723	2016-01-19	US09555043B2	2017-01-31	John Mervyn David Storey; James Peter Sinclair; Colin Marshall; Han Wan Tan; Claude Michel Wischik
This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt-formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallization (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases.
76	Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion	US10801986	2004-03-16	US20050209295A1	2005-09-22	Leonard Kohn; Douglas Goetz; Norikazu Hari; Chris Lewis; Cesidio Giuliani; Giorgio Napolitano; Nilesh Dagia
The present invention relates to novel compounds and methods of use for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. In particular, methimazole derivatives and tautomeric cyclic thiones have the ability to inhibit the adhesion and the migration of leukocytes. In addition to being active anti-inflammatories, the methimazole derivatives and tautomeric cyclic thiones and their physiologically tolerable salts, derivatives and prodrugs are generally suitable for the treatment (i.e., for the therapy and prophylaxis) of diseases that are based on the interaction between VCAM-1 and its ligands or can be influenced by an inhibition of this interaction. In particular, the methimazole derivatives and tautomeric cyclic thiones are suitable for the treatment of diseases that are caused at least partly by an undesired extent of leukocyte adhesion and/or leukocyte migration or are connected therewith, and for whose prevention, alleviation or cure the adhesion and/or migration of leukocytes should be decreased.
77	실질적으로 순수한 메틸티오니늄 클로라이드 5수화물 형태 A의 제조 방법	KR1020127009858	2010-09-23	KR101728574B1	2017-04-19	힐피커롤프; 라거티모
현탁액의상 평형, 결정화또는용매증발에의해메틸티오니늄클로라이드로부터실질적으로순수한메틸티오니늄클로라이드 5수화물형태 A를제조하고, 여기서, 용매의수분함량은 25℃에서의 0.4 이상의수분활성도에해당하고, 습도, 압력및 온도의이의안정성범위내에상기메틸티오니늄클로라이드 5수화물형태 A의건조를제어한다.
78	Method and an apparatus for simultaneous removal of thiosalts and nitrogen compounds in waste water	US14430916	2013-09-20	US20150251937A1	2015-09-10	Jan-Eric Sundkvist; Amang Saleh
The present invention relates to a method and as apparatus for simultaneous removal of thiosalts and nitrogen compounds in waste water, wherein the amount of thiosalts in the waste water is larger than the stoichiometric demand for the autotrophic nitrogen removal. The apparatus comprises a bioreactor (1) including an autotrophic bacteria culture carrying out a denitrification process using the thiosalts as electron donors, having an inlet (3) for receiving the waste water, and an outlet (4) for discharging the purified water. The apparatus comprises an oxygen supply device (6) arranged to supply oxygen to the water in the reactor and a control unit (10) arranged to control the content of dissolved oxygen in the reactor such that the excess of thiosalts is oxidized by the oxygen at the same time as the denitrification process is maintained.
79	황산칼슘 및 알루미늄산 칼슘 광물성 화합물을 포함하는 중질 모르타르용 에트린가이트 결합제	KR1020047017229	2003-04-24	KR100966117B1	2010-06-28	아마티유,로리스; 투조,브루노
본 발명은 황산 칼슘 및 알루미늄산 칼슘 광물성 화합물을 포함하는 중질 모르타르용 에트린가이트 결합제에 관한 것으로서, 상기 알루미늄산 칼슘 광물성 화합물은 칼슘 C 및 알루미늄 A 산화물을 포함하고, 수용성이며 하나 이상의 결정질 및/또는 비정질 광물학적 상들로 결합되고, 상기 알루미늄산 칼슘 광물성 화합물의 유효 C/A 몰비는 1.2~2.7이며 유효 (C+A) 상의 중량 합은 상기 광물성 화합물의 전체 중량의 적어도 30%인 관계에 있는 것을 특징으로 하는 중질 모르타르용 에트린가이트 결합제. 에트린가이트, 결합제, 모르타르
80	황산칼슘 및 알루미늄산 칼슘 광물성 화합물을 포함하는 중질 모르타르용 에트린가이트 결합제	KR1020047017229	2003-04-24	KR1020050016372A	2005-02-21	아마티유,로리스; 투조,브루노
본 발명은 황산 칼슘 및 알루미늄산 칼슘 광물 조성물을 포함하는 중질 모르타르용 에트린가이트 결합제에 관한 것으로서, 상기 알루미늄산 칼슘 광물 조성물은 칼슘 C 및 알루미늄 A 산화물을 포함하고, 수용성이며 하나 이상의 결정질 및/또는 비정질 광물학적 상들로 결합되고, 상기 알루미늄산 칼슘 광물 조성물의 유효 C/A 몰비는 1.2~2.7이며 유효 (C+A) 상의 중량 합은 상기 광물 조성물의 전체 중량의 적어도 30%인 관계에 있는 것을 특징으로 하는 중질 모르타르용 에트린가이트 결합제.

1 2 3 4 5 6 7 8 9 10

IPRDB

热门服务

关于我们

友情链接

联系方式